Monitoring response and resistance to treatment in chronic myeloid leukemia

Current Oncology

Volumn 18, Issue 2, 2011, Pages

  Assouline, S ^a   Lipton, J H ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic myeloid leukemia; Drug monitoring; Drug resistance; Imatinib; Protein kinase inhibitors

Indexed keywords

ALPHA INTERFERON; ANTINEMATODAL AGENT; AP 24534; BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; BUSULFAN; CYTARABINE; DASATINIB; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; NILOTINIB; PEGINTERFERON ALPHA; SGX 393; TOZASERTIB; UNCLASSIFIED DRUG; XL 228;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MOLECULAR CLONING; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PLEURA EFFUSION; PROGNOSIS; QT PROLONGATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT PLANNING; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 79955405214     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i2.391     Document Type: Article

References (110)

1. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer 2005;103:2099-2108.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
3. de Lavadelle H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
5. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973-988.
6. Hochhaus A, Dreyling M on behalf of the ESMO Guidelines Working Group. Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up. Ann Oncol 2008;19(suppl 2):ii63-ii64.
7. Chase A, Huntly BJ, Cross NC. Cytogenetics of chronic myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:553-4571.
8. Knudson RA, Shearer BM, Ketterling RP. Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-fish) strategy: comparison and application to fish minimal residual disease testing in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 2007;175:8-18.
9. Issa S, Holdsworth D, Oei P, Browett PJ. The utility of peripheral blood fish in the quantitation of BCR/ABL in CML patients on imatinib mesylate: a comparison with bone marrow fish and conventional cytogenetics [abstract 2942]. Blood 2004;104:. [Available online at: www.abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;104/11/2942; cited March 30, 2010]
10. Mark HF, Sokolic RA, Mark Y. Conventional cytogenetics and fish in the detection of BCR/ABL fusion in chronic myeloid leukemia (CML). Exp Mol Pathol 2006;81:1-7.
11. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
12. Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology Am Soc Hematol EDUC Program 2006;211-218.
13. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. V.2.2010. Fort Washington, PA: NCCN; 2010.
14. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-858.
15. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-799.
16. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
17. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-2932.
18. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL rna predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13:6136-6143.
19. Laneuville P, Barnett MJ, Bélanger R, et al. Recommendations of the Canadian consensus group on the management of chronic myeloid leukemia. Curr Oncol 2006;13:201-221.
20. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437-4444.
21. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
22. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of C-ABL in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236-4243.
23. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000;289:1938-1942.
24. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006;125:93-106.
25. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-2196.
26. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767-1773.
27. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005;103:1659-1669.
28. Soverini S, Colarossi S, Gnani A, et al. Contribution of Abl kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the gimema Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-7379.
29. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-1029.
30. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
31. Soverini S, Martinelli G, Amabile M, et al. Denaturinghplc-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem 2004;50:1205-1213.
32. Kang HY, Hwang JY, Kim SH, Goh HG, Kim M, Kim DW. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica 2006;91:659-662.
33. Hayette S, Michallet M, Baille ML, Magaud JP, Nicolini FE. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. Leuk Res 2005;29:1073-1077.
34. Kreuzer KA, le Coutre P, Landt O, et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 2003;82:284-289.
35. Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:658-663.
36. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006;20:29-41.
37. Ernst T, Erben P, Muller MC, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186-192.
38. Khorashad JS, de Lavadelle H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806-4813.
39. Sessions J. Chronic myeloid leukemia in 2007. Am J Health Syst Pharm 2007;64(suppl 15):S4-S9.
40. Cortes J, Talpaz M, O'Brien S, et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 1998;16:3279-3285.
41. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:671-684.
42. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794-800.
43. O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103:451-455.
44. Larson RA, Druker BJ, Guilhot FA, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the iris study. Blood 2008;111:4022-4028.
45. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-3499.
46. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-894.
47. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-106.
48. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-294.
49. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-329.
50. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006;62:97-112.
51. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
52. Barnes DJ, Palaiologou D, Panousopoulou E, et al. BCR-ABL expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005;65:8912-8919.
53. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-3745.
54. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373.
55. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. Hoct 1 and resistance to imatinib. Blood 2005;106:1133-1134.
56. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hoct1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258-264.
57. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881-3888.
58. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698.
59. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64:672-677.
60. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279:34227-34239.
61. Wu J, Meng F, Kong LY, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of Lyn kinase. J Natl Cancer Inst 2008;100:926-939.
62. Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551-560.
63. Jabbour E, Kantarjian H, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standarddose imatinib therapy. Blood 2009;113:2154-2160.
64. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-2097.
65. Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther 2008;8:99-110.
66. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505.
67. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-5797.
68. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (enu)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-2338.
69. O'Hare T, Eide CA, Deininger MW. BCR-ABL kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242-2249.
70. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or intolerant patients with chronic myeloid leukemia in blast crisis. Leukemia 2008;22:2176-2183.
71. Apperley J, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the start a trial. J Clin Oncol 2009;27:3472-3479.
72. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-2309.
73. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-5150.
74. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-1206.
75. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract 7009]. J Clin Oncol 2008;26(suppl):374s.
76. Kantarjian HM, Lévy V, Pasquini R, et al. Dasatinib or highdose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136-4147.
77. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212.
78. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546.
79. Kantarjian H, Giles F, Pinilla-Ibarz J, et al. Update on imatinibresistant chronic myeloid leukemia patients in chronic phase (CMLCP) on nilotinib therapy at 24 months: clinical response, safety and long-term outcomes [abstract 1129]. Blood 2009;114:464s.
80. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of SRC and ABL kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-381.
81. Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual BCR-ABL/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005;106:3948-3954.
82. Cortes J, Kantarjian HM, Kim DW, et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib [abstract 1098]. Blood 2008;112:. [Available online at: www.abstracts.hematologylibrary.org/cgi/content/abstract/112/11/1098; cited March 30, 2010]
83. Kantarjian H, le Coutre P, Cortes J, et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010;116:2665-2672.
84. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drugresistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-11016.
85. Giles J, Cortes J, Bergstrom DA, et al. MK-0457, a novel multikinase inhibitor, is active in patients with chronic myeloid leukemia and acute lymphocytic leukemia with the T315I BCR-ABL resistance mutation and patients with refractory JAK-2 positive myeloproliferative diseases [abstract 0927]. Haematologica 2007;92(suppl 1):347.
86. Cortes J, Talpaz M, Deininger M, et al. A phase I trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations [abstract 643]. Blood 2009;114:267s.
87. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997;89:1616-1620.
88. Lipton JH, Khoroshko N, Golenkov A, et al. Phase ii, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kDa) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 2007;48:497-505.
89. Talpaz M, Rakhit A, Rittweger K, et al. Phase i evaluation of a 40-kDa branched-chain long-acting pegylated ifn-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 2005;11:6247-6255.
90. O'Hare T, Eide CA, Deininger MW. New BCR-ABL inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008;17:865-878.
91. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248-55.
92. Stone RM, Donohue KA, Stock W, et al. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: calgb study 19804. Cancer Chemother Pharmacol 2009;63:859-864.
93. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007;110:4005-4011.
94. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204-4210.
95. Khorashad JS, Milojkovic D, Mehta P, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008;111:2378-2381.
96. Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007;92:401-404.
97. Müller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-4953.
98. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCRABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562-2569.
99. Quintas-Cardama A, Cortes J. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leuk Res 2008;32:1313-1316.
100. Baranska M, Lewandowski K, Gniot M, Iwola M, Lewandowska M, Komarnicki M. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. J Appl Genet 2008;49:201-203.
101. O'Hare T, Walters DK, Stoffregen EP, et al. Combined ABL inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: SRC/ABL inhibitors are compatible with imatinib. Clin Cancer Res 2005;11(pt 1):6987-6993.
102. Weisberg E, Catley L, Wright RD, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007;109:2112-2120.
103. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914.
104. Porkka K, Khoury J, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficiency is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-386.
105. Novartis Pharmaceuticals Corporation. Tasigna (Nilotinib) Prescribing Information [United States]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
106. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008;112:516-518.
107. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood 2007;109:4686-4692.
108. Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109:1556-1560.
109. Apperley JF. Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program 2006;:226-232.
110. le Coutre P, Schwarz M, Kim TD. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. Clin Cancer Res 2010;16:1771-1780.